Free CME from PeerView

Continuing Nursing Education (CNE) Activities

Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider
StartThis activity expired on March 31, 2024; credit is no longer available.
Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider
Media: Enduring Material
Activity Release Date: December 21, 2022
Activity Expiration Date: March 31, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, internists, primary care physicians (MDs/DOs/NPs/PAs), HIV care providers, HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), and other clinicians involved in the care of people at risk for being exposed to HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives
- Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice
- Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection
- Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition
Accreditation, Support, and Credit



![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., PVI, PeerView Institute for Medical Education, and HealthHIV. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour(s) and 0.13 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-126-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Hyman Scott, MD, MPH
Bridge HIV, San Francisco Department of Public Health
Assistant Professor
Department of Medicine
University of California
San Francisco, California
Hyman Scott, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina
David Alain Wohl, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; Theratechnologies Inc.; and ViiV
Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Patient Advocate/Planner
Omar Martinez, JD, MPH, MS
Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, PVI, PeerView Institute for Medical Education, and HealthHIV, our educational partners, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on March 31, 2024; credit is no longer available.
Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider
Media: Enduring Material
Activity Release Date: December 21, 2022
Activity Expiration Date: March 31, 2024
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures.
Target Audience
This activity has been designed to meet the educational needs of infectious disease specialists, internists, primary care physicians (MDs/DOs/NPs/PAs), HIV care providers, HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), and other clinicians involved in the care of people at risk for being exposed to HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives
- Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice
- Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection
- Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition
Accreditation, Support, and Credit



![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., PVI, PeerView Institute for Medical Education, and HealthHIV. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour(s) and 0.13 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-126-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Hyman Scott, MD, MPH
Bridge HIV, San Francisco Department of Public Health
Assistant Professor
Department of Medicine
University of California
San Francisco, California
Hyman Scott, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina
David Alain Wohl, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen
Pharmaceuticals, Inc.; Merck & Co., Inc.; Theratechnologies Inc.; and ViiV
Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co.,
Inc.
Patient Advocate/Planner
Omar Martinez, JD, MPH, MS
Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, PVI, PeerView Institute for Medical Education, and HealthHIV, our educational partners, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care
StartThis activity expired on December 19, 2023; credit is no longer available.
Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care
Activity Description and Educational Objectives
Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options.
Upon completion of this activity, participants should be better able to:
- Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis
- Identify patients with psoriasis who are most likely to benefit from novel oral treatments
- Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines
- Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis
Target Audience
This activity has been designed to meet the educational needs of advanced practice clinicians (NPs/PAs), physicians, and other healthcare professionals that provide care to patients with psoriasis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD/IPCE
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: December 20, 2022 - December 19, 2023
Time to Complete: 30 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma
Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals
Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Arcutis
Biotherapeutics, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron
Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB,
Inc.
Presenter
Douglas DiRuggiero, DMSc, MHS, PA-C
Rome Dermatology Center
Rome, Georgia
Douglas DiRuggiero, DMSc, MHS, PA-C, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Lilly;
Novartis Pharmaceuticals Corporation; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Amgen Inc.; Lilly;
Novartis Pharmaceuticals Corporation; and UCB, Inc.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6902-22-T.
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on December 19, 2023; credit is no longer available.
Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care
Activity Description and Educational Objectives
Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options.
Upon completion of this activity, participants should be better able to:
- Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis
- Identify patients with psoriasis who are most likely to benefit from novel oral treatments
- Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines
- Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis
Target Audience
This activity has been designed to meet the educational needs of advanced practice clinicians (NPs/PAs), physicians, and other healthcare professionals that provide care to patients with psoriasis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD/IPCE
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: December 20, 2022 - December 19, 2023
Time to Complete: 30 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.
Chair
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma
Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals
Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Arcutis
Biotherapeutics, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron
Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB,
Inc.
Presenter
Douglas DiRuggiero, DMSc, MHS, PA-C
Rome Dermatology Center
Rome, Georgia
Douglas DiRuggiero, DMSc, MHS, PA-C, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Lilly;
Novartis Pharmaceuticals Corporation; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Amgen Inc.; Lilly;
Novartis Pharmaceuticals Corporation; and UCB, Inc.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development
and review of this activity have disclosed no relevant financial
relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The Penn State College of Medicine designates this enduring material for a
maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Information about CME credit for this activity is available by contacting
Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference
course # G6902-22-T.
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, and Penn State College of
Medicine are responsible for the selection of this activity’s topics, the
preparation of editorial content, and the distribution of this activity. Our
activities may contain references to unapproved products or uses of these
products in certain jurisdictions. The preparation of PeerView activities is
supported by educational grants subject to written agreements that clearly
stipulate and enforce the editorial independence of PVI and Penn State
College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Critical Conversations on Venous Thromboembolism: A MasterClass Series on DVT and PE
StartThis activity expired on December 15, 2023; credit is no longer available.
Critical Conversations on Venous Thromboembolism: A MasterClass Series on DVT and PE
Media: Enduring Material
Activity Release Date: December 16, 2022
Activity Expiration Date: December 15, 2023
Time to Complete Activity: 75 minutes
Activity Description
In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Target Audience
This activity has been designed to meet the educational needs of oncologists, emergency medicine physicians, hematologists, hospitalists, vascular medicine specialists, cardiologists, pulmonologists, critical care specialists, surgeons, and other clinicians involved in the care of patients at risk for or with VTE.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply evidence-based tools to improve the identification of patients at risk for VTE
- Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer
- Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE
- Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Alexander (Ander) T. Cohen, MBBS, MSc, MD, FRACP, FESC, FRCP
Department of Haematological Medicine
Guys and St Thomas' NHS Foundation Trust
King's College London
London, England, United Kingdom
Alexander (Ander) T. Cohen, MBBS, MSc, MD, FRACP, FESC, FRCP, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Bristol Myers
Squibb/Pfizer; and Daiichi Sankyo Co., Ltd.
Grant/Research Support from AstraZeneca; Bayer AG; Bristol Myers
Squibb/Pfizer; and Daiichi Sankyo Co., Ltd.
Speaker for AstraZeneca; Bayer AG; Bristol Myers Squibb/Pfizer;
and Daiichi Sankyo Co., Ltd.
Other Financial or Material Support as an independent contractor
for AbbVie Inc.; AstraZeneca; Bayer AG; Bristol Myers
Squibb/Pfizer; and Daiichi Sankyo Co., Ltd.
Co-Chair/Planner
Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC
Professor of Medicine - University of Queensland and Ochsner Clinical
School
System Chairman of Hospital Medicine
Medical Director of Regional Business Development
Ochsner Health System
New Orleans, Louisiana
Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-052-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on December 15, 2023; credit is no longer available.
Critical Conversations on Venous Thromboembolism: A MasterClass Series on DVT and PE
Media: Enduring Material
Activity Release Date: December 16, 2022
Activity Expiration Date: December 15, 2023
Time to Complete Activity: 75 minutes
Activity Description
In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Target Audience
This activity has been designed to meet the educational needs of oncologists, emergency medicine physicians, hematologists, hospitalists, vascular medicine specialists, cardiologists, pulmonologists, critical care specialists, surgeons, and other clinicians involved in the care of patients at risk for or with VTE.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply evidence-based tools to improve the identification of patients at risk for VTE
- Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer
- Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE
- Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Alexander (Ander) T. Cohen, MBBS, MSc, MD, FRACP, FESC, FRCP
Department of Haematological Medicine
Guys and St Thomas' NHS Foundation Trust
King's College London
London, England, United Kingdom
Alexander (Ander) T. Cohen, MBBS, MSc, MD, FRACP, FESC, FRCP, has a
financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Bristol Myers
Squibb/Pfizer; and Daiichi Sankyo Co., Ltd.
Grant/Research Support from AstraZeneca; Bayer AG; Bristol Myers
Squibb/Pfizer; and Daiichi Sankyo Co., Ltd.
Speaker for AstraZeneca; Bayer AG; Bristol Myers Squibb/Pfizer;
and Daiichi Sankyo Co., Ltd.
Other Financial or Material Support as an independent contractor
for AbbVie Inc.; AstraZeneca; Bayer AG; Bristol Myers
Squibb/Pfizer; and Daiichi Sankyo Co., Ltd.
Co-Chair/Planner
Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC
Professor of Medicine - University of Queensland and Ochsner Clinical
School
System Chairman of Hospital Medicine
Medical Director of Regional Business Development
Ochsner Health System
New Orleans, Louisiana
Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-052-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?
StartThis activity expired on November 14, 2023; credit is no longer available.
Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?
Media: Enduring Material
Activity Release Date: November 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes
Activity Description
This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care.
Target Audience
This activity has been designed to meet the educational needs of the key care team clinicians in the best position to positively impact safety, survival, and QoL outcomes of patients with advanced PC who require ADT, including urologists, medical oncologists, radiation oncologists, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other allied healthcare professionals.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes
- Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors
- Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Daniel J. George, MD
Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
Funding for this Independent Medical Education Activity is provided from Pfizer Inc and Myovant Sciences Ltd.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-050-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on November 14, 2023; credit is no longer available.
Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?
Media: Enduring Material
Activity Release Date: November 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes
Activity Description
This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care.
Target Audience
This activity has been designed to meet the educational needs of the key care team clinicians in the best position to positively impact safety, survival, and QoL outcomes of patients with advanced PC who require ADT, including urologists, medical oncologists, radiation oncologists, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other allied healthcare professionals.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes
- Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors
- Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Daniel J. George, MD
Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
Funding for this Independent Medical Education Activity is provided from Pfizer Inc and Myovant Sciences Ltd.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-050-H01-P
Type of Activity: Application
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates
StartThis activity expired on October 26, 2023; credit is no longer available.
Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates
Media: Enduring Material
Activity Release Date: October 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 45 minutes
Activity Description
Metastatic urothelial carcinoma (UC) is a devastating illness with limited
treatment options, especially for patients who have been previously treated
with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational
activity features two experts in a lively discussion about this rapidly
evolving treatment landscape. The activity also features a patient and his
caregiver’s perspective on their first-hand experience with the treatment
strategies and his journey.
These experts review the latest data and ongoing research on platinum-based
chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the
treatment of bladder cancer and discuss the management of adverse events
associated with novel therapeutics.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice oncology clinicians (NPs and PAs), oncology nurses, and other interprofessional cancer care team members who manage patients with urothelial carcinoma (UC)
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations
- Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care
- Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Meyer Cancer Center
Weill Cornell Medicine
New York, New York
Scott T. Tagawa, MD, MS, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AAA/Novartis Pharmaceuticals
Corporation; AbbVie Inc.; AIkido Pharma Inc.; Amgen Inc.; Astellas Pharma US,
Inc.; Bayer Corporation; Blue Earth Diagnostics; Clarity Pharmaceuticals;
Clovis Oncology; Convergent Therapeutics, Inc.; Dendreon Pharmaceuticals LLC;
EMD Serono, Inc.; Eisai Inc.; Endocyte; Genentech, Inc.; Genomic Health,
Inc.; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; Karyopharm;
Medivation, Inc.; Myovant Sciences Ltd.; Pfizer; POINT Biopharma Global Inc.;
QED Therapeutics, Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.;
Telix Pharmaceuticals Limited; and Tolmar Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma
US, Inc.; AstraZeneca; ATLAB Pharma; AVEO Pharmaceuticals, Inc.; Bayer
Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Clovis Oncology; Dendreon Pharmaceuticals LLC; Endocyte; Genentech,
Inc.; Gilead Sciences, Inc.; Immunomedics, Inc.; INOVIO Pharmaceuticals;
Janssen Pharmaceuticals, Inc.; Karyopharm; Lilly; Medivation, Inc.; Merck &
Co., Inc.; Millennium Pharmaceuticals, Inc; NewLink Genetics; Novartis
Pharmaceuticals Corporation; POINT Biopharma Global Inc.; Progenics
Pharmaceuticals, Inc.; Rexahn Pharmaceuticals; sanofi-aventis U.S. LLC; and
Seattle Genetics, Inc.
Stock Shareholder in AIkido Pharma Inc.
Other Financial or Material Support Patent for Gilead Sciences,
Inc.; Immunomedics, Inc.; and Weill Medical College.
Faculty/Planner
Amie Patel, RN, BSN, MS, CCRC
Research Nurse Specialist
Genitourinary Oncology
Meyer Cancer Center
Weill Cornell Medical Center
New York Presbyterian Hospital
New York, New York
Amie Patel, RN, BSN, MS, CCRC, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Rosario Ardizzone
Rosario Ardizzone has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 26, 2023; credit is no longer available.
Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates
Media: Enduring Material
Activity Release Date: October 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 45 minutes
Activity Description
Metastatic urothelial carcinoma (UC) is a devastating illness with limited
treatment options, especially for patients who have been previously treated
with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational
activity features two experts in a lively discussion about this rapidly
evolving treatment landscape. The activity also features a patient and his
caregiver’s perspective on their first-hand experience with the treatment
strategies and his journey.
These experts review the latest data and ongoing research on platinum-based
chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the
treatment of bladder cancer and discuss the management of adverse events
associated with novel therapeutics.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice oncology clinicians (NPs and PAs), oncology nurses, and other interprofessional cancer care team members who manage patients with urothelial carcinoma (UC)
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations
- Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care
- Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Meyer Cancer Center
Weill Cornell Medicine
New York, New York
Scott T. Tagawa, MD, MS, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AAA/Novartis Pharmaceuticals
Corporation; AbbVie Inc.; AIkido Pharma Inc.; Amgen Inc.; Astellas Pharma US,
Inc.; Bayer Corporation; Blue Earth Diagnostics; Clarity Pharmaceuticals;
Clovis Oncology; Convergent Therapeutics, Inc.; Dendreon Pharmaceuticals LLC;
EMD Serono, Inc.; Eisai Inc.; Endocyte; Genentech, Inc.; Genomic Health,
Inc.; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; Karyopharm;
Medivation, Inc.; Myovant Sciences Ltd.; Pfizer; POINT Biopharma Global Inc.;
QED Therapeutics, Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.;
Telix Pharmaceuticals Limited; and Tolmar Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma
US, Inc.; AstraZeneca; ATLAB Pharma; AVEO Pharmaceuticals, Inc.; Bayer
Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Clovis Oncology; Dendreon Pharmaceuticals LLC; Endocyte; Genentech,
Inc.; Gilead Sciences, Inc.; Immunomedics, Inc.; INOVIO Pharmaceuticals;
Janssen Pharmaceuticals, Inc.; Karyopharm; Lilly; Medivation, Inc.; Merck &
Co., Inc.; Millennium Pharmaceuticals, Inc; NewLink Genetics; Novartis
Pharmaceuticals Corporation; POINT Biopharma Global Inc.; Progenics
Pharmaceuticals, Inc.; Rexahn Pharmaceuticals; sanofi-aventis U.S. LLC; and
Seattle Genetics, Inc.
Stock Shareholder in AIkido Pharma Inc.
Other Financial or Material Support Patent for Gilead Sciences,
Inc.; Immunomedics, Inc.; and Weill Medical College.
Faculty/Planner
Amie Patel, RN, BSN, MS, CCRC
Research Nurse Specialist
Genitourinary Oncology
Meyer Cancer Center
Weill Cornell Medical Center
New York Presbyterian Hospital
New York, New York
Amie Patel, RN, BSN, MS, CCRC, has no financial interests/relationships or affiliations in relation to this activity.
Patient/Planner
Rosario Ardizzone
Rosario Ardizzone has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?
StartThis activity expired on November 20, 2023; credit is no longer available.
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?
Activity Description
How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
- Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
- Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
- Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management
Target Audience
This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).
All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.
Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio
Milind Desai, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers
Squibb; Cytokinetics, Incorporated; and Medtronic.
Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Neal K. Lakdawala, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics,
Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya
Therapeutics.
Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics,
Incorporated; Pfizer; and Renovacor, Inc.
Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education
Margery Tamas, MPH, has a financial interest/relationship or affiliation
in the form of:
Consultant for Fresenius Medical Care North America.
Accreditation, Credit, and Support


![]() |
In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Nurses
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
![]() |
The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P. |
Reciprocity
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Off-Label Disclosure
This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on November 20, 2023; credit is no longer available.
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?
Activity Description
How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
- Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
- Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
- Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management
Target Audience
This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).
All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.
Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio
Milind Desai, MD, MBA, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers
Squibb; Cytokinetics, Incorporated; and Medtronic.
Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Neal K. Lakdawala, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics,
Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya
Therapeutics.
Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics,
Incorporated; Pfizer; and Renovacor, Inc.
Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education
Margery Tamas, MPH, has a financial interest/relationship or affiliation
in the form of:
Consultant for Fresenius Medical Care North America.
Accreditation, Credit, and Support


![]() |
In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Nurses
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
![]() |
The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P. |
Reciprocity
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Off-Label Disclosure
This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer
StartCME/MOC/NCPD/IPCE Information Content
This activity expired on October 16, 2023; credit is no longer available.
Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer
Media: Enduring Material
Activity Release Date: October 17, 2022
Activity Expiration Date: October 16, 2023
Time to Complete Activity: 60 minutes
Activity Description
Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events.
Target Audience
This activity has been designed to meet the educational needs of oncologists, oncology staff nurses, advanced practice nurses, nurse navigators, and other care team professionals who manage patients with HR+/HER2- early breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer
- Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration
- Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs)
- Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Womens Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for ARC Therapeutics; AstraZeneca;
Athenex, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines;
Bristol Myers Squibb; Certara, USA; Chugai Pharmaceutical Co., Ltd.; CytomX
Therapeutics, Inc.; Daiichi Sankyo Inc.; Eisai Inc.; Ellipses Pharma; 4D
pharma; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.;
Infinity Therapeutics; Lilly; Merck & Co., Inc.; Mersana Therapeutics;
Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc; OncoSec
Medical Incorporated; OncXerna Therapeutics, Inc.; Pfizer; Reveal
Genomics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Zentalis; and
Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb;
Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co.,
Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals
Corporation; Pfizer; sanofi-aventis U.S. LLC; and Seattle Genetics,
Inc.
Co-Chair/Planner
Elahe Salehi, DNP, ANP-BC
Breast Oncology Center
Dana-Farber Cancer Institute
Director of Advanced Practice Nursing
Division of Womens Cancers
Boston, Massachusetts
Elahe Salehi, DNP, ANP-BC, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

In support of improving patient care, PVI,
PeerView Institute for Medical Education, is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 1.0 MOC points and patient safety MOC credit in
the American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the
healthcare team, and learners will receive 1.0 Interprofessional Continuing
Education (IPCE) credit for learning and change.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
CME/MOC/NCPD/IPCE Information Content
This activity expired on October 16, 2023; credit is no longer available.
Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer
Media: Enduring Material
Activity Release Date: October 17, 2022
Activity Expiration Date: October 16, 2023
Time to Complete Activity: 60 minutes
Activity Description
Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events.
Target Audience
This activity has been designed to meet the educational needs of oncologists, oncology staff nurses, advanced practice nurses, nurse navigators, and other care team professionals who manage patients with HR+/HER2- early breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer
- Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration
- Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs)
- Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Womens Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for ARC Therapeutics; AstraZeneca;
Athenex, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines;
Bristol Myers Squibb; Certara, USA; Chugai Pharmaceutical Co., Ltd.; CytomX
Therapeutics, Inc.; Daiichi Sankyo Inc.; Eisai Inc.; Ellipses Pharma; 4D
pharma; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.;
Infinity Therapeutics; Lilly; Merck & Co., Inc.; Mersana Therapeutics;
Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc; OncoSec
Medical Incorporated; OncXerna Therapeutics, Inc.; Pfizer; Reveal
Genomics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Zentalis; and
Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb;
Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co.,
Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals
Corporation; Pfizer; sanofi-aventis U.S. LLC; and Seattle Genetics,
Inc.
Co-Chair/Planner
Elahe Salehi, DNP, ANP-BC
Breast Oncology Center
Dana-Farber Cancer Institute
Director of Advanced Practice Nursing
Division of Womens Cancers
Boston, Massachusetts
Elahe Salehi, DNP, ANP-BC, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

In support of improving patient care, PVI,
PeerView Institute for Medical Education, is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME
activity, which includes participation in the evaluation component, enables
the participant to earn up to 1.0 MOC points and patient safety MOC credit in
the American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the
healthcare team, and learners will receive 1.0 Interprofessional Continuing
Education (IPCE) credit for learning and change.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care
StartThis activity expired on November 14, 2023; credit is no longer available.
Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care
Media: Enduring Material
Activity Release Date: October 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes
Activity Description
Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now!
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists (pediatric and adult), allergists/immunologists (pediatric and adult), specialty NPs and PAs, and other healthcare professionals involved in the care of patients with eosinophilic esophagitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease
- Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment
- Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Sandeep K. Gupta, MD
Medical Director for Research
Community Health Network
Professor of Clinical Pediatrics
Pediatric Gastroenterology/Hepatology/Nutrition
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana
Sandeep K. Gupta, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Abbott; Adare Pharma Solutions;
Celgene Corporation; Gossamer Bio, Inc.; QOL Medical, LLC; Takeda Pharmaceuticals U.S.A., Inc.; and ViaSkin.
Grant/Research Support from AstraZeneca; Ellodi Pharmaceuticals; and
National Institutes of Health (NIH).
Faculty/Planner
Gregory M. Constantine, MD
Clinician-Scientist - Eosinophilic Disorders
Allergy/Immunology
Bethesda, Maryland
Gregory M. Constantine, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Amanda B. Muir, MD
Attending Physician
Assistant Professor of Pediatrics
Department of Pediatrics
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Amanda B. Muir, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squib; Medtronic; and
Nexstone Immunology.
Grant/Research Support from Morphic Therapeutic.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on November 14, 2023; credit is no longer available.
Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care
Media: Enduring Material
Activity Release Date: October 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes
Activity Description
Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now!
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists (pediatric and adult), allergists/immunologists (pediatric and adult), specialty NPs and PAs, and other healthcare professionals involved in the care of patients with eosinophilic esophagitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease
- Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment
- Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Faculty/Planner
Sandeep K. Gupta, MD
Medical Director for Research
Community Health Network
Professor of Clinical Pediatrics
Pediatric Gastroenterology/Hepatology/Nutrition
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana
Sandeep K. Gupta, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Abbott; Adare Pharma Solutions;
Celgene Corporation; Gossamer Bio, Inc.; QOL Medical, LLC; Takeda Pharmaceuticals U.S.A., Inc.; and ViaSkin.
Grant/Research Support from AstraZeneca; Ellodi Pharmaceuticals; and
National Institutes of Health (NIH).
Faculty/Planner
Gregory M. Constantine, MD
Clinician-Scientist - Eosinophilic Disorders
Allergy/Immunology
Bethesda, Maryland
Gregory M. Constantine, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Amanda B. Muir, MD
Attending Physician
Assistant Professor of Pediatrics
Department of Pediatrics
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Amanda B. Muir, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squib; Medtronic; and
Nexstone Immunology.
Grant/Research Support from Morphic Therapeutic.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy
StartThis activity expired on October 6, 2023; credit is no longer available.
Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy
Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes
Activity Description
Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS
that is driven by type 2 inflammation and is particularly difficult to
manage, especially when it occurs comorbidly with asthma, as is the case in
up to 60% of patients with CRSwNP. However, biological agents that target
type 2 inflammation and are already approved for other indications (eg,
asthma, atopic dermatitis) have begun to emerge as available therapeutic
options for CRSwNP.
In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical
decision-making for patients with CRSwNP that is based on the latest
evidence, best practice recommendations, and effective interdisciplinary
collaboration.
Target Audience
This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
- Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
- Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Anju T. Peters, MD, MS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose
US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and
Sanofi/Regeneron Pharmaceuticals Inc.
Patient/Planner
Rhonda Nelson
Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 6, 2023; credit is no longer available.
Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy
Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes
Activity Description
Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS
that is driven by type 2 inflammation and is particularly difficult to
manage, especially when it occurs comorbidly with asthma, as is the case in
up to 60% of patients with CRSwNP. However, biological agents that target
type 2 inflammation and are already approved for other indications (eg,
asthma, atopic dermatitis) have begun to emerge as available therapeutic
options for CRSwNP.
In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical
decision-making for patients with CRSwNP that is based on the latest
evidence, best practice recommendations, and effective interdisciplinary
collaboration.
Target Audience
This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
- Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
- Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Anju T. Peters, MD, MS, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose
US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and
Sanofi/Regeneron Pharmaceuticals Inc.
Patient/Planner
Rhonda Nelson
Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes
StartThis activity expired on November 1, 2023; credit is no longer available.
A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes
Activity Description and Educational Objectives
Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder
that is highly variable in clinical presentation and treatment response.
Traditionally used treatments for gMG are broadly immunosuppressive, do not
target pathogenic immunoglobulin G (IgG) autoantibodies, and provide
insufficient symptom relief with significant side effects. Fortunately,
advances in the understanding of gMG pathogenesis are leading to the
development of new treatment options, including neonatal Fc receptor (FcRn)
modulators such as the recently approved efgartigimod, and rozanolixizumab,
which recently completed phase 3 trials. As with all new and emerging
therapeutics, it is important for clinicians to remain abreast of the latest
data.
At a recent live event, a multidisciplinary panel of experts compared the
safety, efficacy, and tolerability of new treatment options with traditional
therapies for gMG. Audience members received expert advice from the
perspective of a neurologist, pharmacist, and infusion nurse, with the goal
of providing their patients with individualized care through FcRn modulation
therapy.
Upon completion of this activity, participants should be better able to:
- Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
- Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing
Target Audience
This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD/CPE
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.
Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.;
Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and
UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx;
Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention;
Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered
Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends
from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services,
Inc.; and Pfizer.
Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru
Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.
Presenter
Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina
Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.
Accreditation, Credit, and Support


The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Support
This activity is supported by an educational grant from argenx US, Inc.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and the University of
Florida College of Medicine are responsible for the selection of this
activity’s topics, the preparation of editorial content, and the distribution
of this activity. Our activities may contain references to unapproved
products or uses of these products in certain jurisdictions. The preparation
of PeerView activities is supported by educational grants subject to written
agreements that clearly stipulate and enforce the editorial independence of
PVI and the University of Florida College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on November 1, 2023; credit is no longer available.
A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes
Activity Description and Educational Objectives
Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder
that is highly variable in clinical presentation and treatment response.
Traditionally used treatments for gMG are broadly immunosuppressive, do not
target pathogenic immunoglobulin G (IgG) autoantibodies, and provide
insufficient symptom relief with significant side effects. Fortunately,
advances in the understanding of gMG pathogenesis are leading to the
development of new treatment options, including neonatal Fc receptor (FcRn)
modulators such as the recently approved efgartigimod, and rozanolixizumab,
which recently completed phase 3 trials. As with all new and emerging
therapeutics, it is important for clinicians to remain abreast of the latest
data.
At a recent live event, a multidisciplinary panel of experts compared the
safety, efficacy, and tolerability of new treatment options with traditional
therapies for gMG. Audience members received expert advice from the
perspective of a neurologist, pharmacist, and infusion nurse, with the goal
of providing their patients with individualized care through FcRn modulation
therapy.
Upon completion of this activity, participants should be better able to:
- Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
- Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
- Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing
Target Audience
This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD/CPE
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.
Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina
James F. Howard Jr., MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx;
F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.;
Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and
UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx;
Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention;
Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered
Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends
from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services,
Inc.; and Pfizer.
Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru
Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.
Presenter
Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina
Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.
Accreditation, Credit, and Support


The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Support
This activity is supported by an educational grant from argenx US, Inc.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and the University of
Florida College of Medicine are responsible for the selection of this
activity’s topics, the preparation of editorial content, and the distribution
of this activity. Our activities may contain references to unapproved
products or uses of these products in certain jurisdictions. The preparation
of PeerView activities is supported by educational grants subject to written
agreements that clearly stipulate and enforce the editorial independence of
PVI and the University of Florida College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
StartThis activity expired on October 28, 2023; credit is no longer available.
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes
Activity Description
Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
- Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
- Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals,
Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol
Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.;
Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC;
Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics
Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier
Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research
funding goes to institution.
Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Amir T. Fathi, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals,
Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.;
Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb;
EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.;
ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics;
MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health;
and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals,
Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers
Squibb.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 28, 2023; credit is no longer available.
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes
Activity Description
Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
- Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
- Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Naval Daver, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals,
Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol
Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.;
Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC;
Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics
Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma
Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics;
Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi
Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier
Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research
funding goes to institution.
Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Amir T. Fathi, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals,
Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.;
Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb;
EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.;
ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics;
MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health;
and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals,
Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers
Squibb.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
StartThis activity expired on October 28, 2023; credit is no longer available.
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes
Activity Description
Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
- Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL
- Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; and Merck & Co., Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-104-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight
Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG
Therapeutics, Inc.
Co-Chair/Planner
Deborah M. Stephens, DO
Associate Professor
Director for Lymphoid Malignancies Program
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah
Deborah M. Stephens, DO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; Bristol Myers Squibb; CSL Behring; Celgene Corporation; Epizyme, Inc.;
Genentech, Inc.; Lilly; and TG Therapeutics, Inc.
Grant/Research Support from Acerta Pharma; Juno Pharmaceuticals;
MingSight Pharmaceuticals, Inc.; Newave Pharmaceutical Inc.; and Novartis
Pharmaceuticals Corporation.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 28, 2023; credit is no longer available.
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes
Activity Description
Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
- Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL
- Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; and Merck & Co., Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-104-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Nicole Lamanna, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Adaptive Biotechnologies;
AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
and Pharmacyclics LLC.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene, Inc.;
Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight
Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG
Therapeutics, Inc.
Co-Chair/Planner
Deborah M. Stephens, DO
Associate Professor
Director for Lymphoid Malignancies Program
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah
Deborah M. Stephens, DO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; Bristol Myers Squibb; CSL Behring; Celgene Corporation; Epizyme, Inc.;
Genentech, Inc.; Lilly; and TG Therapeutics, Inc.
Grant/Research Support from Acerta Pharma; Juno Pharmaceuticals;
MingSight Pharmaceuticals, Inc.; Newave Pharmaceutical Inc.; and Novartis
Pharmaceuticals Corporation.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies
StartThis activity expired on October 28, 2023; credit is no longer available.
Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies
Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes
Activity Description
This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
- Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
- Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers
Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.;
Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene
Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend
Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers
Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.;
Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A.,
Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 28, 2023; credit is no longer available.
Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies
Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes
Activity Description
This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
- Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
- Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application
Faculty Disclosures
Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Sagar Lonial, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers
Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.;
Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company
Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda
Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.
Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene
Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend
Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers
Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.;
Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A.,
Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
StartThis activity expired on October 26, 2023; credit is no longer available.
The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes
Activity Description
Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
- Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
- Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
- Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board
or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals
Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.;
Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F.
Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen
Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.;
Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC
Chair.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 26, 2023; credit is no longer available.
The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes
Activity Description
Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
- Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
- Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
- Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education
activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for
Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge
Faculty Disclosures
Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD, has a financial interest/relationship or affiliation in
the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board
or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals
Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.;
Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F.
Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen
Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.;
Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC
Chair.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
For pharmacists, upon receipt of the completed activity evaluation, you will
receive an email from email@email.peerviewpress.com within 2 weeks. MLI will
accept your completed evaluation form for up to 30 days and will
report your participation to the NABP only if you provide your NABP
e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your
participation record at the NABP website: https://nabp.pharmacy/.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity’s topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies
StartThis activity expired on September 13, 2023; credit is no longer available.
Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies
Media: Enduring Material
Activity Release Date: September 14, 2022
Activity Expiration Date: September 13, 2023
Time to Complete Activity: 30 minutes
Activity Description
Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations.
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the care of patients with DLBCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL)
- Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting
- Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity
- Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Nurse Practitioner
Hematology/Oncology
Swedish Cancer Institute
Seattle, Washington
Sonia Glennie, ARNP MSN OCN AGPCNP-BC, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb/Celgene Corporation; Pharmacyclics LLC/Janssen Pharmaceuticals,
Inc.
Faculty/Planner
Amy Goodrich, CRNP
Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Amy Goodrich, CRNP, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc; AstraZeneca; BeiGene;
Fresenius Kabi; Genentech, Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from ADC Therapeutics America, Inc., Incyte Corporation, and MorphoSys US Inc.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
ILNA Coding Statement
The program content has been reviewed by the Oncology Nursing
Certification Corporation (ONCC) and is acceptable for recertification points
as follows:
0.50 point: Care Continuum, Care of the Pediatric Hematology and Oncology
Patient, Cellular Collection, Preparative Regimens, and Infusion,
Disease-Related Biology, Early Post-Transplant Management, Foundations of
Transplant, Late Post-Transplant Management, Oncologic Emergencies, Oncology
Nursing Practice, Professional Practice/Performance, Symptom Management,
Palliative Care, Supportive Care, Transplant Process and Infusion,
Treatment
The numerical value(s) indicated above is the maximum amount of points that
can be claimed in each subject area domain. The total amount of points
claimed may not exceed the total amount of nursing continuing professional
development (NCPD) or CME awarded from this course and may only apply to the
credential being renewed.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on September 13, 2023; credit is no longer available.
Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies
Media: Enduring Material
Activity Release Date: September 14, 2022
Activity Expiration Date: September 13, 2023
Time to Complete Activity: 30 minutes
Activity Description
Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations.
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the care of patients with DLBCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL)
- Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting
- Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity
- Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Nurse Practitioner
Hematology/Oncology
Swedish Cancer Institute
Seattle, Washington
Sonia Glennie, ARNP MSN OCN AGPCNP-BC, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb/Celgene Corporation; Pharmacyclics LLC/Janssen Pharmaceuticals,
Inc.
Faculty/Planner
Amy Goodrich, CRNP
Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Amy Goodrich, CRNP, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc; AstraZeneca; BeiGene;
Fresenius Kabi; Genentech, Inc.; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from ADC Therapeutics America, Inc., Incyte Corporation, and MorphoSys US Inc.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
ILNA Coding Statement
The program content has been reviewed by the Oncology Nursing
Certification Corporation (ONCC) and is acceptable for recertification points
as follows:
0.50 point: Care Continuum, Care of the Pediatric Hematology and Oncology
Patient, Cellular Collection, Preparative Regimens, and Infusion,
Disease-Related Biology, Early Post-Transplant Management, Foundations of
Transplant, Late Post-Transplant Management, Oncologic Emergencies, Oncology
Nursing Practice, Professional Practice/Performance, Symptom Management,
Palliative Care, Supportive Care, Transplant Process and Infusion,
Treatment
The numerical value(s) indicated above is the maximum amount of points that
can be claimed in each subject area domain. The total amount of points
claimed may not exceed the total amount of nursing continuing professional
development (NCPD) or CME awarded from this course and may only apply to the
credential being renewed.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This NCPD Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief
StartThis activity expired on September 11, 2023; credit is no longer available.
An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief
Activity Description and Educational Objectives
In this animated activity, Dr. Brooks D. Cash shares expert
guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC,
highlighting key differential diagnoses to rule out and alarm features that
warrant further investigation.
You will be able to translate the latest clinical findings related to current
over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as
well as gain insight into the clinical use of newer/novel treatment
options.
Dr. Cash also shares effective communication strategies you can use with your
patients to increase their participation in their care and maximize their
treatment satisfaction.
Upon completion of this activity, participants should be better able to:
- Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
- Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
- Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD/CPE
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals;
and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC;
and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.
Patient Advocate
Johannah Ruddy, MEd
Johannah Ruddy, MEd, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch
Health Companies Inc.
Other Financial or Material Support as an independent contractor for
Salix/Bausch Health Companies Inc.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Support
This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer's product labeling.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and the AGA Institute are
responsible for the selection of this activity's topics, the preparation of
editorial content, and the distribution of this activity. Our activities may
contain references to unapproved products or uses of these products in
certain jurisdictions. The preparation of PeerView activities is supported by
educational grants subject to written agreements that clearly stipulate and
enforce the editorial independence of PVI and the AGA Institute.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on September 11, 2023; credit is no longer available.
An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief
Activity Description and Educational Objectives
In this animated activity, Dr. Brooks D. Cash shares expert
guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC,
highlighting key differential diagnoses to rule out and alarm features that
warrant further investigation.
You will be able to translate the latest clinical findings related to current
over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as
well as gain insight into the clinical use of newer/novel treatment
options.
Dr. Cash also shares effective communication strategies you can use with your
patients to increase their participation in their care and maximize their
treatment satisfaction.
Upon completion of this activity, participants should be better able to:
- Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
- Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
- Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. There are no prerequisites and
there is no fee to participate in this activity or to receive CME/NCPD/CPE
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals;
and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC;
and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.
Patient Advocate
Johannah Ruddy, MEd
Johannah Ruddy, MEd, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch
Health Companies Inc.
Other Financial or Material Support as an independent contractor for
Salix/Bausch Health Companies Inc.
Other PVI staff who may potentially review content for this activity have
disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have
been mitigated.
Accreditation, Credit, and Support


The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Support
This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.
![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer's product labeling.
About This CME/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, and the AGA Institute are
responsible for the selection of this activity's topics, the preparation of
editorial content, and the distribution of this activity. Our activities may
contain references to unapproved products or uses of these products in
certain jurisdictions. The preparation of PeerView activities is supported by
educational grants subject to written agreements that clearly stipulate and
enforce the editorial independence of PVI and the AGA Institute.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
StartThis activity expired on September 1, 2023; credit is no longer available.
Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
- Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
- Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
- Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Faculty Disclosures
Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York
Alexander Drilon, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation
Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX,
Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint
Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos,
Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn
Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo
Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics;
Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE
Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology
Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare
Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD
Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media;
Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra
Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to
Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho
Oncology, Inc; and Teva Pharmaceuticals USA, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity's topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on September 1, 2023; credit is no longer available.
Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC
Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
- Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
- Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
- Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.
Physician Continuing Medical Education
Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Faculty Disclosures
Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York
Alexander Drilon, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation
Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX,
Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint
Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos,
Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn
Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo
Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics;
Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE
Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology
Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare
Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD
Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media;
Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra
Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to
Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho
Oncology, Inc; and Teva Pharmaceuticals USA, Inc.
All of the relevant financial relationships listed have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
In order to receive credit, learners must participate in the entire CE
activity. A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is
needed to obtain MOC/CC credit (75% is required for ABS).
For nurses, the post-test and evaluation are required in their entirety and a
score of 70% or higher is needed to obtain Nursing Continuing Professional
Development (NCPD) contact hours.
About This CME/MOC/NCPD Activity
PVI, PeerView Institute for Medical Education, and Medical Learning
Institute, Inc. are responsible for the selection of this activity's topics,
the preparation of editorial content, and the distribution of this CE
activity. Our activities may contain references to unapproved products or
uses of these products in certain jurisdictions. The preparation of PeerView
activities is supported by educational grants subject to written agreements
that clearly stipulate and enforce the editorial independence of PVI and
Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
StartThis activity expired on October 1, 2023; credit is no longer available.
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
- Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
- Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG;
Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo
Oncology, Inc.
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.;
Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation;
Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
confirmation of submission to CPE Monitor Service. PVI, PeerView Institute
for Medical Education, will accept your completed evaluation form for up to
30 days and will report your participation to the NABP only if you provide
your NABP e-Profile number and date of birth. Within 6 weeks, you can view
your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on October 1, 2023; credit is no longer available.
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes
Activity Description
Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
- Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
- Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG;
Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo
Oncology, Inc.
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.;
Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation;
Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit

![]() |
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
confirmation of submission to CPE Monitor Service. PVI, PeerView Institute
for Medical Education, will accept your completed evaluation form for up to
30 days and will report your participation to the NABP only if you provide
your NABP e-Profile number and date of birth. Within 6 weeks, you can view
your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence
StartThis activity expired on August 29, 2023; credit is no longer available.
Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence
Expert commentary is based on data presented at the American Society of
Clinical Oncology (ASCO) 2022 Annual Meeting.
Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes
Activity Description
In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.
Target Audience
This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
- Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
- Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California
Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.;
GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana
Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.
Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California
Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.
Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on August 29, 2023; credit is no longer available.
Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence
Expert commentary is based on data presented at the American Society of
Clinical Oncology (ASCO) 2022 Annual Meeting.
Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes
Activity Description
In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.
Target Audience
This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
- Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
- Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California
Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.;
GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana
Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.
Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California
Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.
Support
This educational activity is supported by an educational grant from GlaxoSmithKline.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
![]() |
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care
StartThis activity expired on August 25, 2023; credit is no longer available.
A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care
Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
- Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
- Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri
Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or
affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.
Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC
Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
This activity expired on August 25, 2023; credit is no longer available.
A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care
Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes
Activity Description
In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.
Target Audience
This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
- Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
- Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri
Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or
affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.
Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC
Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit


![]() |
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
![]() |
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView